Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Full description
This is a Phase 1/2 study of GEN1107, a protein tyrosine K 7 (PTK7) targeted antibody-drug conjugate (ADC), to evaluate the safety, tolerability, PK, and antitumor activity of GEN1107 in participants with advanced solid tumors, including ovarian cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastroesophageal cancer, and urothelial cancer. This study consists of 2 parts, Part A: Dose Escalation and Dose Level Expansion and Part B: Tumor Specific Expansion.
In Part A, GEN1107 will be administered in different dosing regimens via intravenous (IV) infusion.
Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from Part A in up to 4 different tumor-specific cohorts of up to 40 participants per cohort.
Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Part A:
Pathologically confirmed diagnosis of one of the following tumor types:
Ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)
Endometrial cancer (any subtype excluding sarcoma)
Triple negative breast cancer (TNBC)
Non-small cell lung cancer (NSCLC)
Part B:
Participants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy as specified below:
Measurable disease at baseline as defined per RECIST, Version 1.1
Exclusion Criteria
Additional protocol defined inclusion/exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
280 participants in 1 patient group
Loading...
Central trial contact
Genmab Trial Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal